XOVOLTIB 30MG DESCRIPTION This is a phase 2 study that examines the performance of a cancer drug known as Xovoltib 30mg . Xovoltib 30 mg Tablets prohibit EGFR protein, which accepts to be included in the growth management of chordoma tumors. This study is planned especially for chordoma patients 18 years of age or older, with recurrent or metastatic tumors. Xovoltib 30 mg which is used as a prescription drug under the guidance of the oncologist. INDICATION Xovoltib 30 mg Tablets is used for first-line treatment for patients with metastatic small cell lung cancer (NSCLC) MECHANISM OF ACTION The Afatinib mechanism by preventing the activity of a group of proteins known as epidermal growth factor receptors (EGFRs). The epidermal growth factor receptor is a protein that is included in the growth and spread of cancer cells; Afatinib works by inhibiting the action of this protein. Afatinib should not be taken by people who have EGFR-ne...